| General Information | |
|---|---|
| ZINC ID | ZINC000028570278 |
| Molecular Weight (Da) | 447 |
| SMILES | O=c1c2nn(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2ncn1Cc1ccccc1 |
| Molecular Formula | C24Cl2N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 123.168 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| LogP | 6.623 |
| Activity (Ki) in nM | 3.9811 |
| Polar Surface Area (PSA) | 52.71 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.157 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 27 |
| Fraction csp3 | 0.04 |
| Ilogp | 3.72 |
| Xlogp3 | 5.6 |
| Wlogp | 5.6 |
| Mlogp | 4.9 |
| Silicos-it log p | 5.14 |
| Consensus log p | 4.99 |
| Esol log s | -6.52 |
| Esol solubility (mg/ml) | 0.000135 |
| Esol solubility (mol/l) | 0.0000003 |
| Esol class | Poorly sol |
| Ali log s | -6.47 |
| Ali solubility (mg/ml) | 0.000152 |
| Ali solubility (mol/l) | 0.00000033 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.49 |
| Silicos-it solubility (mg/ml) | 0.00000014 |
| Silicos-it solubility (mol/l) | 3.25E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.05 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.2 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.11 |
| Logd | 4.224 |
| Logp | 4.483 |
| F (20%) | 0.056 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 98.30% |
| Vdss | 1.347 |
| Fu | 1.19% |
| Cyp1a2-inh | 0.556 |
| Cyp1a2-sub | 0.148 |
| Cyp2c19-inh | 0.908 |
| Cyp2c19-sub | 0.081 |
| Cl | 6.383 |
| T12 | 0.106 |
| H-ht | 0.13 |
| Dili | 0.986 |
| Roa | 0.095 |
| Fdamdd | 0.089 |
| Skinsen | 0.411 |
| Ec | 0.003 |
| Ei | 0.071 |
| Respiratory | 0.176 |
| Bcf | 2.195 |
| Igc50 | 5.108 |
| Lc50 | 6.499 |
| Lc50dm | 5.481 |
| Nr-ar | 0.003 |
| Nr-ar-lbd | 0.063 |
| Nr-ahr | 0.797 |
| Nr-aromatase | 0.965 |
| Nr-er | 0.89 |
| Nr-er-lbd | 0.544 |
| Nr-ppar-gamma | 0.963 |
| Sr-are | 0.934 |
| Sr-atad5 | 0.44 |
| Sr-hse | 0.891 |
| Sr-mmp | 0.925 |
| Sr-p53 | 0.96 |
| Vol | 429.803 |
| Dense | 1.038 |
| Flex | 0.138 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.36 |
| Synth | 2.317 |
| Fsp3 | 0.042 |
| Mce-18 | 26 |
| Natural product-likeness | -1.355 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |